Qlife: LOI (Letter of intent) with major industry player in China for Egoo Health.
Qlife: LOI (Letter of intent) with major industry player in China for Egoo Health.
Qlife's management met Hipro Biotechnology's CEO and CSO on this years AACC (Annual Scientific Meeting & Clinical Lab Expo) conference. Now they enter into LOI. Expect a signed agreement later this year.
We host CEO Thomas Warthoe next week for a closer look at the opportunities in China and the agreement with Hipro Biotechnology.
Read full announcement here: Hipro Biotechnology
Participate in next weeks event: Event 19 september 2023
Disclaimer: HC Andersen Capital receives payment from Qlife Holding for a DigitalIR/Corporate Visibility agreement.
Qlife Holding
Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarkers and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. The first capsules in the company's product, Egoo.Health Platform, were CE-marked for professional use in early 2020. The company has patent protection for key parts of its technology. The Danish-based company is listed on Nasdaq First North Stockholm.
Read more on company page